To scroll text in this page

Global Navigation
Global Navigation end

About Astellas Title Image

Start of the main text

2011 News Releases

About RSS

Administration of H5N1 Influenza Vaccine ASP7373 Completed in Phase II Clinical Trial

November 11, 2011

Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the recombinant influenza HA vaccine (H5N1) ASP7373 (former code: UMN-0501) was successfully completed in the currently ongoing phase II clinical trial. Astellas Pharma has been pursuing drug development of this vaccine in cooperation with UMN Pharma Inc. (Headquarters, Akita; CEO, Shu-ichi Kanazashi).

 

This clinical study enrolled 180 healthy adult volunteers, and aims to comparatively evaluate the immunogenicity and safety among the three doses of ASP7373 to determine the optimal clinical dose. ASP7373 was administered intramuscularly two times with three weeks interval.

 

The recombinant influenza HA vaccine (H5N1) ASP7373 has been produced by the cell-culture manufacturing method employing the Baculovirus Expression Vector System (BEVS), a next-generation technology platform for manufacturing of biopharmaceutical products. UMN Pharma started the clinical development of ASP7373 in 2008 and has already completed three clinical studies in Japan.

 

######
 

 

Printer-friendly version


Main Text end
Local Navigation
Local Navigation end
Related Links